stockrowIncannex Healthcare Inc.
IXHLHealthcare Drug Manufacturers Specialty & Generic
Incannex Healthcare Inc.’s revenue for fiscal 2025 (year ended June 2025) was $86,000.00, up 616.7% from fiscal 2024.
- Revenue
- −92.3%
- EPS
- +98.6%
- Free cash flow
- +327.7%
Quarter to June 2026, against a year earlier
Follow IXHL
Alert me
Incannex Healthcare Inc. (IXHL) Piotroski F-score
Incannex Healthcare Inc.'s Piotroski F-score for fiscal 2025 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 3 | 0.00 |
| FY2024 | 3 | (2.00) |
| FY2023 | 5 | (1.00) |
| FY2022 | 6 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (250.09%) | (90.42%) | Fail | 0 |
| Positive operating cash flow | (12.51m) | (15.84m) | Fail | 0 |
| Rising return on assets | (250.09%) | (90.42%) | Fail | 0 |
| Cash flow above net income | 34.37m | 2.61m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 2.86 | 2.88 | Fail | 0 |
| No new shares issued | 1,148,000 | 538,300 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.00 | 0.00 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| TXMD TherapeuticsMD, Inc. compare | 6 |
| INCR InterCure Ltd. compare | 5 |
| SCYX SCYNEXIS, Inc. compare | 5 |
| CPHI China Pharma Holdings, Inc. compare | 5 |
| RMTI Rockwell Medical, Inc. compare | 3 |
| AYTU Aytu BioPharma, Inc. compare | 3 |
| IXHL Incannex Healthcare Inc. | 3 |
| ZYBT Zhengye Biotechnology Holding Limited compare | 2 |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover